Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDBJCY)

Drug Name

3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one Drug Info

Synonyms

3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one; 3-hydroxy-4-methylbenzo[c]chromen-6-one; CHEMBL203519; 76244-77-4; CBMicro_031406; AC1NT8BO; AC1Q2GPY; Oprea1_200366; SCHEMBL6825266; MolPort-000-688-996; ALBB-015456; ZINC5921519; BDBM50180504; STL466134; AKOS002377900; MCULE-5900160059; NS-02841; BIM-0031475.P001; R5445; 4-Methyl-3-hydroxy-6H-dibenzo[b,d]pyran-6-one; SR-01000229483; SR-01000229483-1; 6H-Dibenzo[b,d]pyran-6-one, 3-hydroxy-4-methyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5348729
TTD Drug ID: DMDBJCY

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated Estrogens	DMLT0E1	Dyspareunia	GA12	Approved	[2]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[3]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[4]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[5]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[6]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[7]
AUS-131	DMUXO3Z	Hot flushes	GA30	Phase 2	[8]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[9]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[10]
VG-101	DMAN21O	Menopause symptom	GA30.0	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72.
2	Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
5	Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
6	MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
7	Company report (Axcentua)
8	S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
9	Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
11	Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.